All content, including text, graphics, images, and information available through this email is for general information purposes only
1 post with this tag Novo Nordisk Lobbies Up to Win Medicare Coverage of Its Weight Loss Drugs The maker of Ozempic and Wegovy has recently hired a dozen new lobbyists to work on the issue of obesity and medication coverage
We use a conservative 65%+ estimate for commercial insurance
The WHO further notes that obesity significantly increases the risk of cardiovascular disease, stroke and type 2 diabetes, while additional research has linked excess weight to chronic kidney disease and rising healthcare expenditures, creating substantial pressure on healthcare systems globally
Work with physician-referred patients Be part of high-demand GLP-1 care teams Build a steady client base Earn based on your availability Deliver real outcomes (not fragmented care) Flexible schedule you control your time What makes this different
Effectiveness and Weight Loss Outcomes Head-to-head comparisons show GLP-1 medications like semaglutide generally produce greater weight loss than Contrave
